A Phase 3 interventional study of Dexamethasone and Daratumumab in Relapsed Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Amgen. Completed at 113 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 14th largest by enrollment, is one of 12 that started in 2017, is one of 24 in phase 3, and was the 25th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 466 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 7th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2017, is one of 11 in phase 3, and was the 35th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
This is a phase 3 multicenter, open-label, randomized study in participants with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior therapies.
Participants receive the treatment determined by randomization for a maximum of approximately 5 years, up to 30 days prior to the final analysis data cutoff (DCO) date or until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or death (whichever occurs first). No crossover between the treatment arms is allowed.
This was an open-label study. However, the assessment of response and disease progression for the primary analysis was determined by an Independent Review Committee (IRC) in a blinded manner. Sensitivity analyses of response and disease progression were determined centrally by the sponsor using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]) in a blinded manner.
Following progression or discontinuation of study drug(s), participants will have 1 follow-up visit (30 days [+3} after last dose of all study drug[s]). After disease progression, data on survival status and subsequent antimyeloma therapy will be gathered at long-term follow-up (LTFU) visits every 12 weeks (+/-2 weeks) until the Final Analysis DCO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16. Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.
Drug: Dexamethasone · Drug: Carfilzomib
Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16. Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days. Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only.
Drug: Dexamethasone · Drug: Daratumumab · Drug: Carfilzomib
Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
Also known as: DARZALEX®
Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes. Dose could be modified based on a \>20% change in body weight or toxicity.
Also known as: KYPROLIS®
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)
Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). The duration of PFS was right censored for participants who met any of the following conditions: 1. no baseline/post-baseline disease assessments; 2. started a new anti myeloma therapy before documentation of progressive disease or death; 3. progressive disease or death immediately after more than 70 days without disease assessment visit or; 4. alive without documentation of disease progression before the analysis trigger date (PA DCO); 5. lost to follow-up or withdrawn consent.
Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)
Overall response rate was defined as the percentage of participants in each treatment group who achieve partial response (PR) or better per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) as their best response. Complete Response (CR): No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-component with urine M-component \<100 mg/24 hours. Partial Response (PR): ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. 95% CIs for proportions were estimated using the Clopper-Pearson method.
Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee
MRD\[-\]CR at 12 months was defined as achievement of CR per IMWG-URC by IRC and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (8 to 13 month window).
Time frame: 12 Months (8- to 13-month window)
Overall Survival
Overall survival was defined as the time from randomization until death from any cause. Deaths collected via public source, after end of study were included. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive were censored at the date last known to be alive.
Time frame: Up to 58 months after the first participant was enrolled (at FA DCO, a median of 40.29 weeks of treatment [any study drug] in the Kd group and 79.29 weeks of treatment [any study drug] in the KdD group; FA DCO was 15 Apr 2022)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events are defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are treatment-emergent adverse events considered related to at least one study drug by the investigator, including those with unknown relationship.
Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)
Duration of response (DOR) was defined as the time (in months) from first evidence of partial response (PR) or better per IMWG-URC by IRC to the earlier of disease progression or death due to any cause for participants with a best response of PR or better. For those who are alive and have not experienced disease progression at the time of data cutoff for analysis, duration of response was right-censored. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Time frame: From Day 1 until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Kaplan-Meier Estimate for Time to Next Treatment (TTNT)
Time to next treatment was defined as the time (in months) from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma. Time to next treatment for participants who do not start the subsequent treatment for multiple myeloma was censored at the date when the participant's information was last available. Medians of TTNT duration were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)
Time to progression was defined as the time (in months) from randomization to documented disease progression. Participants who did not have documented disease progression were censored at the date when data was last available.
Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)
Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis. 95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.
Time frame: Randomization to Months 3, 6, 12, and 18
Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)
Time to overall response was defined as the time from randomization to the earliest date a response of partial response (PR) or better as per IMWG-URC is first achieved and subsequently confirmed for participants with a best response of PR or better.
Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More
A measure of the persistence of the CR (includes strict CR) per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) for 12 months or more after achieving MRD\[-\]CR status. 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
Time frame: PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)
The percentage of participants in each treatment group who achieved stringent complete response (sCR) or CR per IMWG-URC, as assessed by the IRC, as their best response is presented.
Time frame: From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months
MRD\[-\] at 12-month was defined as achievement of MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (from 8 months to 13 months window). 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
Time frame: 12 Months (8- to 13-month window)
Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. QLQ-C30 questionnaire was administered prior to dosing every 28 ± 7 days starting from cycle 1 day 1 through first follow-up visit (30 days \[+3\] after last dose of all study drugs).
Time frame: Baseline (Day 1 pre-dose) up to 236.3 weeks (longest treatment duration as of the FA DCO)
This study was conducted at 102 centers. 569 participants were screened and 466 were enrolled. Primary analysis (PA) data cutoff (DCO): 14-Jul-2019. Final analysis (FA) DCO: 15-Apr-2022.
| Milestone | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Started | 154 | 312 |
| Treated | 153 | 308 |
| Completed | 49 | 102 |
| Not completed | 105 | 210 |
| Withdrew: Withdrawal by subject | 14 | 28 |
| Withdrew: Decision by sponsor | 13 | 37 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Death | 74 | 142 |
Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). The duration of PFS was right censored for participants who met any of the following conditions: 1. no baseline/post-baseline disease assessments; 2. started a new anti myeloma therapy before documentation of progressive disease or death; 3. progressive disease or death immediately after more than 70 days without disease assessment visit or; 4. alive without documentation of disease progression before the analysis trigger date (PA DCO); 5. lost to follow-up or withdrawn consent.
| Participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Participants with PFS events | 68 | 110 |
| Participants who were censored | 86 | 202 |
Overall response rate was defined as the percentage of participants in each treatment group who achieve partial response (PR) or better per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) as their best response. Complete Response (CR): No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-component with urine M-component \<100 mg/24 hours. Partial Response (PR): ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. 95% CIs for proportions were estimated using the Clopper-Pearson method.
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only) | 74.7 (67.0 to 81.3) | 84.3 (79.8 to 88.1) |
MRD\[-\]CR at 12 months was defined as achievement of CR per IMWG-URC by IRC and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (8 to 13 month window).
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee | 1.9 (0.4 to 5.6) | 12.8 (9.3 to 17.0) |
Overall survival was defined as the time from randomization until death from any cause. Deaths collected via public source, after end of study were included. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive were censored at the date last known to be alive.
| months | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Overall Survival | 43.6 (35.3 to NA) | 50.8 (44.7 to NA) |
Treatment-emergent adverse events are defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are treatment-emergent adverse events considered related to at least one study drug by the investigator, including those with unknown relationship.
| Participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| PA DCO: All TEAEs | 147 | 306 |
| PA DCO: TEAEs: Severity Grade >=3 | 113 | 253 |
| PA DCO: TEAEs: Serious Adverse Events | 70 | 173 |
| PA DCO: TEAEs: Leading to discon of carfilzomib | 33 | 65 |
| PA DCO: TEAEs: Leading to discon of daratumumab | NA | 28 |
| PA DCO: TEAEs: Leading to discon of dexamethasone | 37 | 33 |
| PA DCO: Fatal TEAEs | 8 | 30 |
| PA DCO: Treatment-related TEAEs | 129 | 260 |
| PA DCO: Related TEAEs: Grade >=3 | 74 | 187 |
| PA DCO: Related and serious TEAEs | 32 | 84 |
| PA DCO: Related TEAEs: discon of carfilzomib | 21 | 50 |
| PA DCO: Related TEAEs: discon of daratumumab | NA | 15 |
| PA DCO: Related TEAEs: discon of dexamethasone | 24 | 19 |
| PA DCO: Related Fatal TEAEs | 0 | 5 |
| FA DCO: All TEAEs | 149 | 306 |
| FA DCO: TEAEs: Severity Grade >=3 | 120 | 273 |
| FA DCO: TEAEs: Serious Adverse Events | 80 | 211 |
| FA DCO: TEAEs: Leading to discontinuation of carfilzomib | 37 | 98 |
| FA DCO: TEAEs: Leading to discontinuation of daratumumab | NA | 43 |
| FA DCO: TEAEs: Leading to discon of dexamethasone | 40 | 58 |
| FA DCO: Fatal TEAEs | 11 | 39 |
| FA DCO: Treatment-related TEAEs | 131 | 267 |
| FA DCO: Related TEAEs: Grade >=3 | 82 | 206 |
| FA DCO: Related and serious TEAEs | 34 | 102 |
| FA DCO: Related TEAEs: discon of carfilzomib | 22 | 69 |
| FA DCO: Related TEAEs: discon of daratumumab | NA | 18 |
| FA DCO: Related TEAEs: discon of dexamethasone | 24 | 30 |
| FA DCO: Related Fatal TEAEs | 0 | 5 |
Duration of response (DOR) was defined as the time (in months) from first evidence of partial response (PR) or better per IMWG-URC by IRC to the earlier of disease progression or death due to any cause for participants with a best response of PR or better. For those who are alive and have not experienced disease progression at the time of data cutoff for analysis, duration of response was right-censored. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
| months | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only) | 16.6 (13.9 to NA) | NA (NA to NA) |
Time to next treatment was defined as the time (in months) from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma. Time to next treatment for participants who do not start the subsequent treatment for multiple myeloma was censored at the date when the participant's information was last available. Medians of TTNT duration were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
| months | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| PA DCO | 17.3 (13.5 to NA) | NA (NA to NA) |
| FA DCO | 17.8 (13.5 to 23.1) | 37.4 (30.1 to 47.8) |
Time to progression was defined as the time (in months) from randomization to documented disease progression. Participants who did not have documented disease progression were censored at the date when data was last available.
| months | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only) | 17.5 (13.2 to NA) | NA (NA to NA) |
Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis. 95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| 3 months | 90.0 (83.7 to 93.9) | 95.3 (92.1 to 97.2) |
| 6 months | 79.4 (71.6 to 85.3) | 86.4 (81.8 to 89.9) |
| 12 months | 62.7 (53.6 to 70.5) | 77.5 (72.1 to 82.0) |
| 18 months | 45.1 (34.5 to 55.4) | 68.5 (62.2 to 74.0) |
Time to overall response was defined as the time from randomization to the earliest date a response of partial response (PR) or better as per IMWG-URC is first achieved and subsequently confirmed for participants with a best response of PR or better.
| months | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only) | 1.5 ± 1.1 | 1.4 ± 1.4 |
A measure of the persistence of the CR (includes strict CR) per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) for 12 months or more after achieving MRD\[-\]CR status. 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| PA DCO | 0.0 (0.0 to 2.4) | 0.0 (0.0 to 1.2) |
| FA DCO | 0.0 (0.0 to 2.4) | 5.8 (3.5 to 9.0) |
The percentage of participants in each treatment group who achieved stringent complete response (sCR) or CR per IMWG-URC, as assessed by the IRC, as their best response is presented.
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only) | 10.4 (6.1 to 16.3) | 28.5 (23.6 to 33.9) |
MRD\[-\] at 12-month was defined as achievement of MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (from 8 months to 13 months window). 95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
| percentage of participants | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months | 5.2 (2.3 to 10.0) | 18.3 (14.1 to 23.0) |
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. QLQ-C30 questionnaire was administered prior to dosing every 28 ± 7 days starting from cycle 1 day 1 through first follow-up visit (30 days \[+3\] after last dose of all study drugs).
| score on a scale | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| Baseline | 66.19 ± 19.19 | 61.79 ± 20.37 |
| Cycle 2 | 64.35 ± 16.25 | 61.00 ± 19.65 |
| Cycle 3 | 66.13 ± 18.12 | 63.10 ± 18.24 |
| Cycle 4 | 66.67 ± 15.01 | 63.47 ± 18.66 |
| Cycle 5 | 67.62 ± 17.19 | 64.45 ± 16.76 |
| Cycle 6 | 68.06 ± 15.80 | 65.92 ± 16.85 |
| Cycle 7 | 69.33 ± 14.68 | 65.73 ± 16.59 |
| Cycle 8 | 69.44 ± 17.82 | 66.34 ± 16.64 |
| Cycle 9 | 65.72 ± 15.90 | 67.82 ± 15.53 |
| Cycle 10 | 68.38 ± 14.56 | 67.98 ± 16.26 |
| Cycle 11 | 67.42 ± 15.24 | 68.52 ± 17.37 |
| Cycle 12 | 65.13 ± 14.94 | 67.47 ± 17.16 |
| Cycle 13 | 67.49 ± 16.51 | 67.00 ± 18.21 |
| Cycle 14 | 67.66 ± 17.03 | 66.12 ± 16.60 |
| Cycle 15 | 69.34 ± 15.31 | 67.61 ± 17.68 |
| Cycle 16 | 68.21 ± 16.44 | 66.41 ± 18.69 |
| Cycle 17 | 69.44 ± 14.92 | 69.81 ± 15.28 |
| Cycle 18 | 66.67 ± 16.50 | 66.29 ± 16.38 |
| Cycle 19 | 69.68 ± 17.50 | 68.00 ± 17.33 |
| Cycle 20 | 71.04 ± 14.49 | 66.43 ± 19.52 |
| Cycle 21 | 70.94 ± 15.87 | 67.42 ± 16.25 |
| Cycle 22 | 68.52 ± 12.30 | 67.51 ± 17.90 |
| Cycle 23 | 69.52 ± 16.41 | 66.67 ± 17.63 |
| Cycle 24 | 68.10 ± 18.24 | 68.00 ± 16.51 |
| Cycle 25 | 67.93 ± 16.15 | 66.21 ± 16.78 |
| Cycle 26 | 70.71 ± 18.65 | 66.12 ± 17.54 |
| Cycle 27 | 65.23 ± 14.78 | 66.52 ± 18.35 |
| Cycle 28 | 63.22 ± 19.61 | 67.28 ± 18.66 |
| Cycle 29 | 66.67 ± 19.25 | 67.22 ± 18.10 |
| Cycle 30 | 67.01 ± 17.63 | 67.23 ± 18.52 |
| Cycle 31 | 68.06 ± 16.24 | 67.33 ± 18.81 |
| Cycle 32 | 66.67 ± 19.62 | 67.91 ± 18.45 |
| Cycle 33 | 67.75 ± 15.35 | 67.95 ± 18.92 |
| Cycle 34 | 68.18 ± 15.78 | 69.86 ± 17.77 |
| Cycle 35 | 65.91 ± 15.62 | 69.51 ± 18.00 |
| Cycle 36 | 63.77 ± 18.22 | 68.22 ± 16.93 |
| Cycle 37 | 67.50 ± 18.91 | 68.63 ± 19.01 |
| Cycle 38 | 65.20 ± 18.69 | 69.25 ± 18.47 |
| Cycle 39 | 64.71 ± 15.46 | 68.38 ± 19.15 |
| Cycle 40 | 58.33 ± 14.25 | 67.74 ± 19.34 |
| Cycle 41 | 66.07 ± 13.26 | 68.46 ± 19.37 |
| Cycle 42 | 63.69 ± 15.19 | 67.16 ± 18.77 |
| Cycle 43 | 67.22 ± 15.89 | 63.30 ± 19.91 |
| Cycle 44 | 61.81 ± 15.27 | 65.50 ± 18.21 |
| Cycle 45 | 67.59 ± 12.11 | 66.87 ± 15.53 |
| Cycle 46 | 64.58 ± 13.91 | 67.89 ± 17.66 |
| Cycle 47 | 66.67 ± 0.00 | 68.52 ± 13.74 |
| Cycle 48 | 61.11 ± 9.62 | 68.56 ± 13.35 |
| Cycle 49 | 61.11 ± 9.62 | 68.42 ± 13.49 |
| Cycle 50 | 61.11 ± 9.62 | 68.75 ± 13.09 |
| Cycle 51 | 63.89 ± 4.81 | 67.36 ± 11.49 |
| Cycle 52 | 54.17 ± 17.68 | 62.04 ± 17.24 |
| Cycle 53 | — | 61.11 ± 9.62 |
| Follow-up | 61.00 ± 23.04 | 59.90 ± 18.02 |
Collected over Treatment-emergent adverse events - any adverse events with an onset after the administration of the first dose of any study treatment and within the end of the study or 30 days of the last dose of any study treatment, whichever occurred earlier. The longest treatment duration as of the FA DCO was 236.3 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kd - Carfilzomib and Dexamethasone | 80/154 (51.9%) | 80/153 (52.3%) | 137/153 (89.5%) |
| KdD - Carfilzomib, Dexamethasone and Daratumumab | 148/312 (47.4%) | 211/308 (68.5%) | 295/308 (95.8%) |
| Event | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| PneumoniaInfections and infestations | 16/153 | 52/308 |
| Acute kidney injuryRenal and urinary disorders | 7/153 | 10/308 |
| PyrexiaGeneral disorders | 4/153 | 14/308 |
| InfluenzaInfections and infestations | 3/153 | 14/308 |
| COVID-19 pneumoniaInfections and infestations | 3/153 | 14/308 |
| SepsisInfections and infestations | 2/153 | 12/308 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/153 | 8/308 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/153 | 7/308 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/153 | 7/308 |
| CataractEye disorders | 3/153 | 9/308 |
| Event | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 46/153 | 119/308 |
| AnaemiaBlood and lymphatic system disorders | 51/153 | 113/308 |
| HypertensionVascular disorders | 47/153 | 113/308 |
| DiarrhoeaGastrointestinal disorders | 27/153 | 112/308 |
| Upper respiratory tract infectionInfections and infestations | 37/153 | 104/308 |
| FatigueGeneral disorders | 29/153 | 80/308 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 34/153 | 68/308 |
| InsomniaPsychiatric disorders | 19/153 | 64/308 |
| NauseaGastrointestinal disorders | 22/153 | 62/308 |
| Back painMusculoskeletal and connective tissue disorders | 20/153 | 61/308 |
Intent to Treat population
| Age, Continuous(years) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Mean | 64.3 ± 9.6 | 62.9 ± 10.0 | 63.4 ± 9.9 |
| Age, Customized(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| 18 - 64 years | 77 | 163 | 240 |
| 65 - 74 years | 55 | 121 | 176 |
| 75 - 84 years | 22 | 28 | 50 |
| >=85 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Female | 63 | 135 | 198 |
| Male | 91 | 177 | 268 |
| Ethnicity (NIH/OMB)(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 7 | 8 |
| Not Hispanic or Latino | 146 | 291 | 437 |
| Unknown or Not Reported | 7 | 14 | 21 |
| Race/Ethnicity, Customized(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Asian | 20 | 46 | 66 |
| Black or African American | 2 | 7 | 9 |
| White | 123 | 243 | 366 |
| Other | 9 | 16 | 25 |
| Frailty Status as Assessed by Investigator(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Fit | 68 | 176 | 244 |
| Intermediate fitness | 36 | 54 | 90 |
| Frail | 9 | 10 | 19 |
| Not available | 37 | 66 | 103 |
| Missing | 4 | 6 | 10 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Disease status 0 or 1 | 147 | 295 | 442 |
| Disease status 2 | 7 | 15 | 22 |
| Missing | 0 | 2 | 2 |
| Time from Initial Diagnosis to Randomization(months) | Kd - Carfilzomib and Dexamethasone | KdD - Carfilzomib, Dexamethasone and Daratumumab | Total |
|---|---|---|---|
| Mean | 44.03 ± 36.57 | 47.86 ± 34.69 | 46.58 ± 35.34 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 113 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2017 to primary completion in Jul 2019, 25 months.
Results were first posted in Sep 2020, 1 year 1 month after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 25 months is below that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab